Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
High, Would be great if they could ring the opening bell every day.
Pick, What specifically convinced you that dilution is near it's end? How much farther does it have to go?
Same here. Let's get some good management performance before they reward themselves.
Sitting here enjoying OPK at $16.92, whether as a waystation to bigger things or just another new hill on our roller coaster. Enjoy the ride!
Edit: gonna crack open a bottle of my nice Jefferson's bourbon and add to the enjoyment.
Grew up a W Sox fan. So sad losing some of their greats from the 59 season this last year. I also had great respect for Ernie Banks.
Let's Play Two.
Hey, Leo could have CTI* pay off his loan and he could invest the proceeds here.
I agree that making a small investment here is worth the risk. The horse's pedigree looks good enough to claim.
Miles, To extend your analogy, aren't you accustomed to striking out? lol. I could not resist that straight line.
Anyhow, NNAB is certainly cheap enough to take a flyer, as we have discussed before. Consider it entering a home run contest.
MilesTeg Thursday, 05/14/15 09:58:41 AM
Re: Ultimate01 post# 177
Post # of 180
Very much agree on the attractive entry point here.
I'm quite literally fretting over nickels and dimes.
I'm very much in a short/long term time frame right now. Meaning, I need some short term stocks that can hit for average, in order to fund some long term stocks that bat .400.
Sorry for the baseball analogy, but it works. :)
I'm not impatient, I just feel my available funds will go further somewhere else at this time. Unless something really turns me off here, I'll be invested in NNAB eventually.
Btw--Be as Frank as you like, as long as you aren't insulting anyone on a personal level, and you are talking investing, I won't delete your posts.
MT
You are shown as the sole Mod.
Miles, If I were a betting man - and we do buy stocks, so a bet is involved - I would guess a private placement with "qualified investors" with the two families buying some of the stock at a 20 percent discount and getting generous warrant coverage to boot. Warrants to be exercisable at $.75 per share for 3 years.
How's that for a specific forecast which I'm bound to be wrong on somewhere or everywhere.
I was listening when it was supposed to start and got no sound and no slides. Then it came on maybe 5 minutes later with the initial part not there.
FUN, I hate to think of all the investments I should or should not have made. ROX is ok so far.
Fun, I am so glad I bought my first position in ROX at .28 in June 2012. I wish I had bought more then. Great hindsight.
For some reason, I can't recall what led me to ROX. Probably an article in SA.
EDIT: I suspect it was when I was starting to follow Dr. Frost as an indicator of good early-stage companies.
Motley Fool mostly just sends the meat of their analyst recommendations to subscribers of the relevant service. Some of the articles also go out through selected media, to get more eyeballs and subscribers.
I'm pleased that they at least gave some teaser coverage to ROX.
Inherently, I have no issue with a reverse split, as long as there is a commensurate reduction in the total shares authorized. If the r/s is just an excuse to issue a ton more shares, I have a problem.
and finally some audio feed and the slides.
Nothing coming thru on my screen. I am signed in.
And a friend of mine maintains hives of honeybees, yet I never seem to see the bees by my house that I remember from childhood. Somehow, the flowers do get pollinated near me.
From Fidelity, news of special BCYP shareholder meeting to vote on reverse split in the range of 10/1 to 50/1.
Financials:
http://biz.yahoo.com/e/150511/nnab10-q.html
(table of contents)
We have incurred $178,523 of operating expenses for the nine months ended March 31, 2015. Prior to inception, the Company's compounds were composed and formulated by researchers at Kard, a preclinical contract research organization founded by our President Rajah Menon in 2002 and of which Mr. Menon is its principal shareholder, who then conducted in-vitro studies. On October 3, 2013, Kard and Mr. Menon assigned all of their rights, formulations, and all studies and data related to efflux pump antibiotics to the Company. We are now engaged in organizational activities and sourcing technology to license. We anticipate incurring other costs associated with equipment purchases and general and administrative expenses, including employee salaries and benefits, legal expenses, and other costs associated with an early stage, publicly-traded company.
The amounts that we actually spend for any specific purpose may vary significantly, and will depend on a number of factors including, but not limited to, the pace of progress of our research and development, market conditions, and our ability to qualify vendors. In addition, we may use a portion of any net proceeds to acquire complementary compounds. We will have significant discretion in the use of any net proceeds. Investors will be relying on the judgment of our management regarding the application of the proceeds of any sale of our Common Stock.
Requirement for Additional Capital
The Company has engaged in limited research and development activities. We currently do not have sufficient funds to meet our planned drug development for the next twelve (12) months and we may not be able to obtain the necessary financing on terms and conditions acceptable to the Company. Assuming that we are successful in raising additional financing, we plan to incur the following expenses over the next twelve (12) months:
? Research and Development of $575,000, which includes planned costs for nano efflux pump inhibitor and nanoantibiotic of $75,000 and an additional $500,000 if we were to license certain nanotechnologies that we are presently reviewing. During the past quarter and presently all our research and development has been put on hold while we negotiate licensing rights with universities and inventors.
? Corporate overhead of $100,000, which includes budgeted legal, accounting and other costs expected to be incurred.
? Licensing and Capital costs of $100,000, which $75,000 is budgeted for acquiring a nanotechnology license, and $25,000 is the estimated cost for equipment to be deployed at vendor sites to be selected; and
? Officer and Staffing costs of $180,000.
The Company had approximately $278,535 of cash on hand at March 31, 2015 and will be unable to proceed with its planned drug development, meet its administrative expense requirements, capital costs, or staffing costs without obtaining additional net financing of approximately $600,000 to meet its budget.
The Company has limited experience with pharmaceutical drug development. As such these budget estimates may not be accurate. In addition, the actual work to be performed is not known at this time, other than a broad outline, as is normal with any scientific work. As further work is performed, additional work may become necessary or change in plans or workload may occur. Such changes may have an adverse impact on our estimated budget. Such changes may also have an adverse impact on our projected timeline of drug development.
Management intends to use capital and debt financing, as required, to fund the Company's operations. There can be no assurance that the Company will be able to obtain the additional capital resources necessary to fund its anticipated obligations for the next twelve (12) months.
Excellent results in Conference call abstract:
http://seekingalpha.com/article/3168896-chimerixs-cmrx-ceo-michelle-berrey-on-q1-2015-results-earnings-call-transcript?part=single
Excerpt:
Let's turn now to the recent BARDA posting of April 13 regarding it’s intend to award a sole source contract to Chimerix for the procurement of brincidofovir for the treatment of smallpox. This represents a significant opportunity for us, as BARDA's total estimated dollar value for the 60-month base period contract is approximately $100 million. If all options are exercised by BARDA, the total dollar value of the contract could reach approximately $435 million. BARDA anticipates announcing the award of this contract in 2H of this year. According to the posted notice of intent, the estimated period of performance for the 60-month base period is September 2015 through August 2020 for initial delivers of brincidofovir to the U.S. Centers for Disease Control and Prevention for the Strategic National Stockpile or SNS.
The options may be exercised at BARDA's discretion to achieve the potential delivery of a maximum of 1.7 million treatment courses. Any award would be subject to negotiation and execution of a definitive agreement by BARDA and Chimerix. As a remainder, the first quarter 2015 financial results as well as this morning's announcement are available on the investor section of our website.
Mostly just bumblebees, wasps and hornets by me.
You're quite welcome.
And the link to Jason's excellent article is:
http://seekingalpha.com/article/3149046-medicinovas-deep-pipeline-is-meaningfully-undervalued?auth_param=irif:1akksid:68bf484c7b883d87edefeea705b2666a&uprof=46
It is very nice coverage and may get MNOV some more eyeballs.
Thank you for posting George!
Now, Thanks. So it's $135 million for EirGen.
Yes, he is always on the lookout for sales as well as purchases. Let's hope for a great sale!
Gingi, Just remember there are always risks.
1. We had shorts actively talking the price down, and that will happen periodically in each of the Frost stocks.
2. We have the continued risk of him passing. While there have been good managers installed at each company, they still are not the legendary Dr.
3. Each of these is a long term play. Yes, swing traders can make money, but long-only investors may have a long wait. I am in that category, but admit to sometimes selling at what seem like peaks and then buying back in lower.
Game, "probably" is correct. We have to remember that he is doing the acquisitions and reorganizations to add value to his holdings. We are simply along for the ride. We do not get the grants of shares. We do not get the discounted prices with warrants unless we participate in one of the private offerings.
I guess we may find out the price around 10k time.
CMRX officer received grant of 2000 shares at $1.53 and sold them at market persuant to a 10b5-1 plan. Those were just preplanned, regular sales and a small part of her ownership.
Yes, that's it. I didn't post details as they were in the newsfeed above the posts.
So the new acquistion by OPK of Eir-Gen seems to me based on Frost having worked with the honchos back at Ivax. I wonder if he bought this as much for it's distribution network in Europe as for it's products.
OK. A mini-uplist!
MD, Montgomery County.
We have county-level price-fixing. No real competition unless I go out of state.
Then, unfortunately, back to blah. Ugh.
Fun, For the first time, I saw Chef's Collaboration on the shelf of my local county liquor store. About $46.
Thank you sir!
I don't mean to hassle you and hope we will all profit from BLRX. I have seen reverse splits work well - mostly when the deal is done just to uplist - and others work poorly, when the intent is to just stay afloat and prevent delisting. GLTU
It's sort of like trading 10 one-cent coins for a dime. They are exactly equivalent.
[quoteboatlife Member Level Thursday, 04/30/15 09:24:54 AM
Re: BackTheTruckUp post# 593
Post # of 607
how so? the ADS was 10 common shares..now the common shares are getting a 1-10 rev split..makes the ADS 1-1 now!!!][/quote]